文献速递眼底病与葡萄膜炎

Pegcetacoplan与Avacincaptad Pegol治疗地图样萎缩相关眼部不良事件:一项基于人群的药物警戒研究

Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study.
PubMed 文献 · Am J Ophthalmol · 2025-04-25

该回顾性药物警戒分析基于FAERS数据库(至2024年12月),评估pegcetacoplan与avacincaptad pegol治疗地图样萎缩的眼部不良事件报告。Pegcetacoplan报告752例不良事件患者,avacincaptad pegol报告80例。Pegcetacoplan报告的前节(虹膜)出血、虹膜新生血管、脉络膜新生血管、眼内注射并发症、出血性闭塞性视网膜血管炎、视网膜闭塞性血管炎及细菌性眼内炎报告比值比显著升高;avacincaptad pegol报告的脉络膜新生血管、玻璃体炎、干性年龄相关性黄斑变性及囊样黄斑水肿报告比值比显著升高。

要点

  • Pegcetacoplan报告的前节(虹膜)出血ROR为1767(95%CI 538-5803)。
  • Pegcetacoplan报告的出血性闭塞性视网膜血管炎ROR为4606(95%CI 2000-10611)。
  • Avacincaptad pegol报告的脉络膜新生血管ROR为1169(95%CI 426-3205)。

核心结论

  • 当前处方模式表明,pegcetacoplan报告的眼部不良事件谱比avacincaptad pegol更广泛。
  • 这些发现旨在增进临床医生对这些药物安全性特征的了解,以支持知情患者照护并提高对这些新型地图样萎缩治疗的警惕性。

研究设计与样本

  • 回顾性药物警戒分析,使用OpenVigil 2.1数据挖掘软件分析FAERS数据库(自建库至2024年12月)。
  • 分析以pegcetacoplan或avacincaptad pegol为主要可疑药物的眼部不良事件报告,共纳入pegcetacoplan相关752例和avacincaptad pegol相关80例不良事件患者。
  • 采用比例失衡分析评估特定药物-不良事件组合相对于数据库中所有其他药物的报告比值比(ROR)。

主要发现

  • Pegcetacoplan报告比例失衡升高的眼部不良事件包括前节(虹膜)出血(ROR 1767,95%CI 538-5803)、虹膜新生血管(ROR 1248,95%CI 502-3099)、脉络膜新生血管(ROR 1328,95%CI 956-1845)、眼内注射并发症(ROR 2552,95%CI 1607-4053)、出血性闭塞性视网膜血管炎(ROR 4606,95%CI 2000-10611)、视网膜闭塞性血管炎(ROR 2352,95%CI 1313-4212)及细菌性眼内炎(ROR 1260,95%CI 613-2589)。
  • Avacincaptad pegol报告比例失衡升高的眼部不良事件包括脉络膜新生血管(ROR 1169,95%CI 426-3205)、玻璃体炎(ROR 782,95%CI 316-1936)、干性年龄相关性黄斑变性(ROR 684,95%CI 316-1936)及囊样黄斑水肿(ROR 445,95%CI 140-1412)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the postmarketing ocular adverse events (AEs) reported for avacincaptad pegol and pegcetacoplan, the only Food and Drug Administration (FDA)-approved treatments for geographic atrophy (GA). DESIGN: Retrospective pharmacovigilance analysis. SUBJECTS: Ocular AE reports in the FDA Adverse Event Reporting System (FAERS) in which pegcetacoplan or avacincaptad pegol was identified as the primary suspect drug were analyzed. METHODS: Using the OpenVigil 2.1 data mining software, we conducted a retrospective pharmacovigilance analysis of the FAERS database from inception to December 2024. We conducted disproportionality analyses to assess reporting odds ratios (RORs) for specific drug-AE combinations compared with all other drugs in the database. MAIN OUTCOME MEASURES: Ocular AEs were evaluated. RESULTS: A total of 752 and 80 patients with AEs secondary to pegcetacoplan and avacincaptad pegol, respectively, were identified. Ocular AEs disproportionately overreported for pegcetacoplan included anterior segment (iris) hemorrhage (ROR 1767, 95% CI 538-5803), iris neovascularization (ROR 1248, 95% CI 502-3099), choroidal neovascularization (ROR 1328, 95% CI 956-1845), intraocular injection complication (ROR 2552, 95% CI 1607-4053), hemorrhagic occlusive retinal vasculitis (ROR 4606, 95% CI 2000-10,611), retinal occlusive vasculitis (ROR 2352, 95% CI 1313-4212), and bacterial endophthalmitis (ROR 1260, 95% CI 613-2589). Ocular AEs disproportionately overreported for avacincaptad pegol included choroidal neovascularization (ROR 1169, 95% CI 426-3205), vitritis (ROR 782, 95% CI 316-1936), dry age-related macular degeneration (ROR 684, 95% CI 316-1936), and cystoid macular edema (ROR 445, 95% CI 140-1412). CONCLUSIONS: Current prescribing patterns indicate that a broader spectrum of ocular AEs were reported for pegcetacoplan than avacincaptad pegol. These findings aim to enhance clinicians' understanding of the safety profiles of these agents, enabling informed patient care and heightened vigilance of these novel GA treatments.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kailani Z, Mihalache A, Popovic MM, et al. Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study. Am J Ophthalmol. 2025. PMID: 40288597. doi:10.1016/j.ajo.2025.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。